文献速递腹部技术与安全MR

ADC值检测克罗恩病患者肠道炎症及生物制剂治疗反应:一项前瞻性试验的事后分析

ADC Values for Detecting Bowel Inflammation and Biologic Therapy Response in Patients With Crohn Disease: A Post Hoc Prospective Trial Analysis.
PubMed 文献 · AJR Am J Roentgenol · 2023-08-16

该研究对89例接受生物制剂治疗的克罗恩病患者在基线和治疗后46周行MR小肠造影,分析586个肠段,评估ADC值识别肠道炎症和治疗反应的表现。基线ADC检测MaRIA评分≥11的AUC为0.92;随访时ADC检测MaRIA评分改善至<11的AUC为0.87,但检测内镜下溃疡愈合的AUC低于MaRIA评分(0.84 vs 0.94,p=.01)。结论不支持用ADC替代MaRIA评分检测生物制剂治疗反应。

要点

  • 基线ADC检测MaRIA评分≥11的AUC为0.92,敏感度78.6%、特异度91.4%。
  • 随访ADC检测MaRIA评分改善至<11的AUC为0.87,敏感度75.4%、特异度83.6%。
  • 检测内镜溃疡愈合时ADC的AUC低于MaRIA评分(0.84 vs 0.94,p=.01)。

核心结论

  • 研究结果不支持用ADC替代MaRIA评分检测生物制剂治疗反应;ADC可能作为评估克罗恩病肠道炎症的辅助手段,但检测生物制剂治疗反应的表现有限。

研究设计与样本

  • 前瞻性试验数据的事后分析,纳入89例接受生物制剂治疗的克罗恩病患者(中位年龄37岁;女49例、男40例),2013年3月至2021年4月期间在基线和治疗后46周行MR小肠造影,其中43例在两个时间点均行回结肠镜检查;分析基于小肠和结直肠肠段水平,共分析586个肠段。

诊断标准与关键数值

  • ADC诊断阈值采用基于初始ROC分析的1301×10⁻⁶ mm²/s;MaRIA评分二分类阈值采用11分(中重度炎症)。基线ADC检测MaRIA评分≥11的肠段:AUC 0.92、敏感度78.6%、特异度91.4%、准确率88.2%。基线检测内镜溃疡:ADC的AUC 0.87、敏感度70.8%、特异度90.2%、准确率85.1%,MaRIA评分的AUC 0.96、敏感度86.2%、特异度96.2%、准确率93.6%(AUC比较p<.001)。随访ADC检测MaRIA评分改善至<11:AUC 0.87、敏感度75.4%、特异度83.6%、准确率80.0%。随访检测内镜溃疡愈合:ADC的AUC 0.84、敏感度70.7%、特异度95.8%、准确率84.4%,MaRIA评分的AUC 0.94、敏感度90.2%、特异度100.0%、准确率95.6%(AUC比较p=.01)。ADC观察者间一致性ICC基线为0.70、随访为0.65。

临床应用与阅片要点

  • 作者结论认为ADC可能作为评估克罗恩病肠道炎症的辅助手段,但检测生物制剂治疗反应的表现有限,研究结果不支持用ADC替代MaRIA评分检测生物制剂治疗反应。

局限性

  • 本文为前瞻性试验数据的事后分析。
  • ADC测量仅由一名观察者完成,第二观察者仅在15例患者中重复测量。
  • ADC观察者间一致性ICC基线为0.70、随访为0.65。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND. New biologic agents for Crohn disease (CD) create a need for noninvasive disease markers. DWI may assess bowel inflammation without contrast agents. OBJECTIVE. The purpose of this study was to evaluate ADC values for identifying bowel inflammation and therapeutic response in patients with CD treated with biologic therapy. METHODS. This study entailed post hoc analysis of prospective trial data. Analysis included 89 patients (median age, 37 years; 49 women, 40 men) with CD treated by biologic therapy who underwent MR enterography (MRE) at baseline and 46 weeks after therapy, from March 2013 to April 2021; 43 patients underwent ileocolonoscopy at both time points. Analysis was conducted at the level of small-bowel and colorectal segments (586 segments analyzed). MR index of activity (MaRIA) score and presence of endoscopic ulcers were determined at both time points. One observer measured bowel wall ADC. Diagnostic performance was evaluated. Dichotomous ADC assessments used a threshold of 1301 × 10-6 mm2/s based on initial ROC analysis; dichotomous MaRIA score assessments used a threshold of 11 (moderate to severe inflammation). A second observer repeated ADC measurements in 15 patients. RESULTS. At baseline, ADC had AUC of 0.92, sensitivity of 78.6%, specificity of 91.4%, and accuracy of 88.2% for detecting segments with MaRIA score 11 or greater. At baseline, AUC for detecting endoscopic ulcers was 0.96 for MaRIA score versus 0.87 for ADC (p < .001); sensitivity, specificity, and accuracy were 70.8%, 90.2%, and 85.1% for ADC and 86.2%, 96.2%, and 93.6% for MaRIA score. At follow-up, ADC had AUC of 0.87, sensitivity of 75.4%, specificity of 83.6%, and accuracy of 80.0% for detecting improvement in MaRIA score to less than 11. At follow-up, AUC for detecting endoscopic ulcer healing was 0.94 for MaRIA score versus 0.84 for ADC (p = .01); sensitivity, specificity, and accuracy were 70.7%, 95.8%, and 84.4% for ADC and 90.2%, 100.0%, and 95.6% for MaRIA score. Interobserver agreement for ADC, based on intraclass correlation coefficient, was 0.70 at baseline and 0.65 at follow-up. CONCLUSION. The findings do not support use of ADC rather than MaRIA scores for detecting biologic therapy response. CLINICAL IMPACT. ADC may have an adjunct role in assessing bowel inflammation in CD, but showed limited performance for detecting biologic therapy response.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Rimola J, Fernandez-Clotet A, Capozzi N, et al. ADC Values for Detecting Bowel Inflammation and Biologic Therapy Response in Patients With Crohn Disease: A Post Hoc Prospective Trial Analysis. AJR Am J Roentgenol. 2023. PMID: 37584507. doi:10.2214/AJR.23.29639

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。